Your browser doesn't support javascript.
SARS-CoV-2 evolution during treatment of chronic infection.
Kemp, Steven A; Collier, Dami A; Datir, Rawlings P; Ferreira, Isabella A T M; Gayed, Salma; Jahun, Aminu; Hosmillo, Myra; Rees-Spear, Chloe; Mlcochova, Petra; Lumb, Ines Ushiro; Roberts, David J; Chandra, Anita; Temperton, Nigel; Sharrocks, Katherine; Blane, Elizabeth; Modis, Yorgo; Leigh, Kendra E; Briggs, John A G; van Gils, Marit J; Smith, Kenneth G C; Bradley, John R; Smith, Chris; Doffinger, Rainer; Ceron-Gutierrez, Lourdes; Barcenas-Morales, Gabriela; Pollock, David D; Goldstein, Richard A; Smielewska, Anna; Skittrall, Jordan P; Gouliouris, Theodore; Goodfellow, Ian G; Gkrania-Klotsas, Effrossyni; Illingworth, Christopher J R; McCoy, Laura E; Gupta, Ravindra K.
  • Kemp SA; Division of Infection and Immunity, University College London, London, UK.
  • Collier DA; Division of Infection and Immunity, University College London, London, UK.
  • Datir RP; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Ferreira IATM; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Gayed S; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Jahun A; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Hosmillo M; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Rees-Spear C; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Mlcochova P; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Lumb IU; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Roberts DJ; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Chandra A; Division of Infection and Immunity, University College London, London, UK.
  • Temperton N; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Sharrocks K; NHS Blood and Transplant, Oxford and BRC Haematology Theme, University of Oxford, Oxford, UK.
  • Blane E; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Modis Y; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Leigh KE; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Canterbury, UK.
  • Smith KGC; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Smith C; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Doffinger R; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Ceron-Gutierrez L; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Barcenas-Morales G; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Pollock DD; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Goldstein RA; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Smielewska A; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.
  • Skittrall JP; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Gouliouris T; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
  • Goodfellow IG; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Gkrania-Klotsas E; Department of Medicine, University of Cambridge, Cambridge, UK.
  • Illingworth CJR; NIHR Cambridge Bioresource, Cambridge, UK.
  • McCoy LE; Department of Virology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.
  • Gupta RK; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
Nature ; 592(7853): 277-282, 2021 04.
Article in English | MEDLINE | ID: covidwho-1387425
ABSTRACT
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for virus infection through the engagement of the human ACE2 protein1 and is a major antibody target. Here we show that chronic infection with SARS-CoV-2 leads to viral evolution and reduced sensitivity to neutralizing antibodies in an immunosuppressed individual treated with convalescent plasma, by generating whole-genome ultra-deep sequences for 23 time points that span 101 days and using in vitro techniques to characterize the mutations revealed by sequencing. There was little change in the overall structure of the viral population after two courses of remdesivir during the first 57 days. However, after convalescent plasma therapy, we observed large, dynamic shifts in the viral population, with the emergence of a dominant viral strain that contained a substitution (D796H) in the S2 subunit and a deletion (ΔH69/ΔV70) in the S1 N-terminal domain of the spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype were reduced in frequency, before returning during a final, unsuccessful course of convalescent plasma treatment. In vitro, the spike double mutant bearing both ΔH69/ΔV70 and D796H conferred modestly decreased sensitivity to convalescent plasma, while maintaining infectivity levels that were similar to the wild-type virus.The spike substitution mutant D796H appeared to be the main contributor to the decreased susceptibility to neutralizing antibodies, but this mutation resulted in an infectivity defect. The spike deletion mutant ΔH69/ΔV70 had a twofold higher level of infectivity than wild-type SARS-CoV-2, possibly compensating for the reduced infectivity of the D796H mutation. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy, which is associated with the emergence of viral variants that show evidence of reduced susceptibility to neutralizing antibodies in immunosuppressed individuals.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Mutagenesis / Evolution, Molecular / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Case report / Prognostic study / Randomized controlled trials Topics: Variants Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03291-Y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Mutagenesis / Evolution, Molecular / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Case report / Prognostic study / Randomized controlled trials Topics: Variants Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03291-Y